Targeted therapies are widely used in cancer because of their effectiveness, 
even in tumours that are resistant to conventional chemotherapy such as kidney 
or hepatocellular carcinomas. There are different families classified according 
to their mode of action. The antiangiogenics block tumor angiogenesis by acting 
on VEGF or its receptor. The main molecules are bevacizumab, sunitinib, and 
sorafinib. HER inhibitors work by blocking these receptors, which control 
different signaling intracellular pathways, and include an inhibitor of HER2, 
trastuzumab, and various inhibitors of HER1, or EGFR, including cetuximab, 
erlotinib, and gefitinib. Inhibitors of KIT, a membrane receptor, are mainly 
represented by imatinib, an inhibitor of tyrosine kinase. Finally, mTOR 
inhibitors act on the signaling pathway PI3K/AKT/mTOR, and key molecules are 
temsirolimus, everolimus, and deforolimus.